New York-listed healthcare company Covidien is reportedly in late stage talks to buy, SuperDimension, an Israel and US-based manufacturer of catheters for lung cancer and disease patients, for $300m. SuperDimension is one of its corporate venturing unit’s portfolio companies.
Globes said the company had raised $120m in its history. Covidien Ventures, and undisclosed existing investors, backed SuperDimension in an $11m series B round last year.
SuperDimension’s last round of funding raised $9.8m, in July 2010, from backers including investment firm OrbiMed Advisors, and venture capital firms Oxford Biosciences Partners, Pitango Venture Capital and Medica Venture Partners.
Alongside the equity funding, SuperDimension also gained a $15m credit facility from the Oxford Finance Corporation in September 2010.
Other backers of the company have been Boston Scientific, Pfizer, as well as venture firms Gemini Israel Funds, Concord Venture Funds , Evergreen Venture Partners and Niztanim.
SuperDimension was founded in 2006 and a detailed feature of its development until 2005, from Windhover Information’s Start-Up magazine is attached.